Edition:
United Kingdom

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

80.58EUR
24 Feb 2017
Change (% chg)

€0.45 (+0.56%)
Prev Close
€80.13
Open
€80.34
Day's High
€80.91
Day's Low
€79.50
Volume
2,439,934
Avg. Vol
2,738,907
52-wk High
€82.45
52-wk Low
€62.50

SASY.PA

Chart for SASY.PA

About

Sanofi SA, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. It operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and... (more)

Overall

Beta: 0.88
Market Cap(Mil.): €104,111.20
Shares Outstanding(Mil.): 1,292.02
Dividend: 2.96
Yield (%): 3.67

Financials

  SASY.PA Industry Sector
P/E (TTM): 23.59 28.83 29.67
EPS (TTM): 3.42 -- --
ROI: 5.02 13.58 13.08
ROE: 7.60 14.47 14.23

BRIEF-FTC approves final order settling charges for Boehringer Ingelheim’s asset swap with Sanofi

* U.S. FTC - Approved final order settling charges that Boehringer Ingelheim’s $13.53 billion asset swap with Sanofi would likely be anticompetitive Source text : (http://bit.ly/2lC10ws) Further company coverage:

24 Feb 2017

How Sanofi lost out to J&J in $30 billion battle for Actelion

ZURICH Swiss biotech company Actelion , days before agreeing to a $30 billion (24 billion pound) bid by Johnson & Johnson , found a rival offer to be as attractive but went with J&J because its offer provided more certainty, a filing showed on Thursday.

16 Feb 2017

How Sanofi lost out to J&J in $30 billion battle for Actelion

ZURICH Swiss biotech company Actelion , days before agreeing to a $30 billion bid by Johnson & Johnson , found a rival offer to be as attractive but went with J&J because its offer provided more certainty, a filing showed on Thursday.

16 Feb 2017

UPDATE 2-How Sanofi lost out to J&J in $30 bln battle for Actelion

* J&J's $280 per share tender offer to start March 3 (Recasts with rival offer, adds background throughout)

16 Feb 2017

Deals of the day-Mergers and acquisitions

Feb 13 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Monday:

13 Feb 2017

BRIEF-Ipsen acquires a portfolio of select consumer healthcare products from Sanofi

* Ipsen to acquire a portfolio of select consumer healthcare products from Sanofi

13 Feb 2017

Drugmaker Ipsen to buy some products from Sanofi for 83 million euros

PARIS Drugmaker Ipsen has agreed to buy five consumer healthcare products from bigger French rival Sanofi for 83 million euros ($88 million), in a deal which Ipsen said should boost its profits.

13 Feb 2017

Drugmaker Ipsen to buy some products from Sanofi for 83 million euros

PARIS Drugmaker Ipsen has agreed to buy five consumer healthcare products from bigger French rival Sanofi for 83 million euros (70.56 million pounds) , in a deal which Ipsen said should boost its profits.

13 Feb 2017

UPDATE 1-Drugmaker Ipsen to buy some products from Sanofi for 83 mln euros

PARIS, Feb 13 Drugmaker Ipsen has agreed to buy five consumer healthcare products from bigger French rival Sanofi for 83 million euros ($88 million), in a deal which Ipsen said should boost its profits.

13 Feb 2017

Sanofi nears deal to sell some over-the-counter drugs to Ipsen - Bloomberg

Feb 12 Drugmaker Sanofi is close to selling some over-the-counter products to Ipsen SA, in a deal that could be valued at nearly 100 million euros ($106.18 million), Bloomberg reported.

13 Feb 2017

More From Around the Web

Earnings vs. Estimates